Form 4: Iteos Therapeutics Director Exercises Stock Options

Director Timothy Van Hauwermeiren exercised stock options for 22,346 shares of Iteos Therapeutics common stock at a price of $4.3 per share.

Summary

• On May 13, 2025, Timothy Van Hauwermeiren, a director of Iteos Therapeutics, Inc., exercised stock options.
• This involved the acquisition of 22,346 shares of common stock at a price of $4.3 per share.
• The exercise was a cash exercise of a stock option without a subsequent sale of the underlying shares.
• Following the transaction, Van Hauwermeiren directly owns 22,346 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (stock option exercise) by a director, indicating confidence but not necessarily a major positive or negative event.

Positives

• The exercise of stock options by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Stock option exercises are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants and exercises are standard practice in the biotech industry to incentivize executives and align their interests with shareholders.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options as part of their compensation packages.
• The size of the grant and exercise price are typical for a director-level position in a company of Iteos Therapeutics' size and stage.

Stakeholder Impact

• The exercise of stock options could have a minor dilutive effect on existing shareholders.

Key Dates

Keywords

stock options, director, Iteos Therapeutics, ITOS, common stock, exercise, Van Hauwermeiren, beneficial ownership